Home Companies Catalysts Deep Dives
AZD9550 AZD9550 PHASE2
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Formulations[]
Companies
AZN (ORIGINATOR)100%
Programs (1)
IndicationStageKey StudyRegional Status
NASHPHASE1—[]
Notes
GLP-1/glucagon RA for obesity.
Data from Supabase · Updated 2026-03-24